转移性前列腺癌的胚系与体细胞基因组检测:ASCO指南
该指南由多学科小组系统检索2018年1月至2024年5月文献,最终纳入14篇文献(8篇系统综述和6项临床试验),推荐转移性前列腺癌患者应同时进行胚系和体细胞DNA测序(基于panel的检测),以指导PARP抑制剂的使用,并指出胚系检测对患者其他癌症筛查及家系成员级联检测的意义。
要点
- 转移性前列腺癌患者应同时接受胚系和体细胞DNA测序(基于panel的检测)。
- 上述检测可指导多聚(ADP-核糖)聚合酶抑制剂的使用,该类药物在转移性去势抵抗性前列腺癌中有生存获益。
- 胚系检测可能对患者其他癌症筛查及家系成员级联检测有提示意义;对于既往阴性或信息不足者可考虑复测,临床状态显著变化时可考虑转移灶活检或ctDNA检测。
核心结论
- 转移性前列腺癌患者应同时进行胚系和体细胞DNA测序(基于panel的检测),以指导PARP抑制剂的使用,并考虑胚系检测对额外癌症筛查和家系级联检测的意义。
研究设计与样本
- 由含患者代表的多学科小组进行系统综述,检索PubMed数据库2018年1月至2024年5月文献,最终纳入14篇文献(8篇系统综述和6项临床试验)。
主要发现
- 文献检索共识别1,713篇论文,应用纳入标准后最终纳入14篇(8篇系统综述和6项临床试验)。
- 支持何时进行重复检测及最佳组织类型(原发肿瘤对比转移灶活检对比循环肿瘤DNA检测)的数据较为有限。
关键数值与推荐
- 推荐转移性前列腺癌患者应同时进行胚系和体细胞DNA测序(基于panel的检测)。
- 上述检测可指导多聚(ADP-核糖)聚合酶抑制剂的使用,该类药物在转移性去势抵抗性前列腺癌中有生存获益。
- 胚系检测可能对患者其他癌症筛查及家系成员级联检测有提示意义。
- 对于既往检测结果阴性或信息不足的患者,本专家组推荐考虑复测;当临床状态发生显著变化时,考虑进行转移灶活检或ctDNA检测。
- 与预后相关(而非预测性)的二代基因组测序发现不应在临床试验之外用于指导治疗。
临床怎么用
- 转移性前列腺癌患者应接受胚系和体细胞DNA测序(基于panel的检测),以指导PARP抑制剂的使用。
- 对于既往检测阴性或信息不足者,可考虑复测;临床状态显著变化时,可考虑转移灶活检或ctDNA检测。
- 仅与预后相关(非预测性)的二代测序发现不应在临床试验之外用于指导治疗。
局限性
- 支持何时进行重复检测及最佳组织类型(原发肿瘤对比转移灶活检对比循环肿瘤DNA检测)的数据较为有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. METHODS: A systematic review by a multidisciplinary panel with patient representation was conducted. The PubMed database was searched from January 2018 to May 2024. Articles were selected for inclusion if they reported on patients with metastatic prostate cancer who received a germline or somatic genomic test and/or made comparisons between those tests, reported detection rates, prognostic information, or treatment implications. RESULTS: A total of 1,713 papers were identified in the literature search. After applying the eligibility criteria, 14 remained: eight systematic reviews and six clinical trials. RECOMMENDATIONS: Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer. In addition, germline testing may have screening implications for additional cancers for patients and cascade testing implications for family members. The data supporting when to perform repeat testing and optimal tissue type to use (eg, primary tumor v metastatic biopsy versus circulating tumor DNA [ctDNA] testing) are more limited, but this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs. Next-generation genomic sequencing findings that are associated with prognostic only (and not predictive) value should not be used to guide treatment outside of a clinical trial.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.
引用
- Yu EY, Rumble RB, Agarwal N, et al. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025. PMID: 39787437. doi:10.1200/JCO-24-02608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。